# Salivary Oxytocin as a Biomarker of Psychedelic Treatment

> **NCT07345858** · — · ENROLLING_BY_INVITATION · sponsor: **University of Geneva, Switzerland** · enrollment: 80 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07345858
- **Lead sponsor:** University of Geneva, Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-01-05
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-10-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07345858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07345858, "Salivary Oxytocin as a Biomarker of Psychedelic Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07345858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*